Agreed, the diminishing job creation numbers in the US would seem to be an indication of a worsening economy. But the real indicator and official definition of a recession is when there are two consecutive quarters of negative economic growth as measured by a country's GDP. Ironically, this can happen despite a buoyant stock market and in fact the S&P was up a whopping 9% in October. Perhaps, this is the final gasp for air in the stock-market before everything comes crashing down?
You might be right about a knock on effect from the Valeant fallout story, although these companies are focusing on different areas of the market and not considered direct competitors. I expect we will continue to see volatility in the biopharm/healthcare sector going forwards. Amgen is only up 0.7% YTD. To avoid the pitfalls of volatile stocks, try to buy on the dip rather than the upswing, and hold for the longer term. Maybe after being hit so hard maybe Valeant is now a buy?
Out of 15 analyst opinions, 2 are a strong buy, 7 are a buy, and 8 are a hold currently. I expect we will continue to see volatility in the biopharm/healthcare sector going forwards. Amgen is only up 0.7% YTD. To avoid the pitfalls of volatile stocks, try to buy on the dip rather than the upswing, and hold for the longer term. Over the past 5 yrs the stock is up 185%.
The stock is up around 48% ytd but there's precious little analyst opinions on the stock with only one opinion - a hold. With a market cap of under $1 bn, is this a gem of a stock that's too small to matter? Look out for earnings release next week Nov 4th.
Nothing injects momentum into oil prices like regional conflict. Perhaps, we just don't have enough of these any more! (that's not a bad thing) True, Opec has a hand in influencing supply and demand but they are only part of the bigger story. Global demand is slowing, US fracking is supplying too much oil, and oil is being stockpiled. China's demand is also slowing as industrial output slows. One thing's for sure, the owners of the some 253 million cars and trucks in the US aren't complaining about sinking oil prices.
Blue bounced back yesterday up almost 3% perhaps as a result of Tuesday's research call: Bluebird Bio, Inc. was given a ‘double your money’ research call on Tuesday. But on the downside, Oppenheimer has the stock as an Outperform rating, and assigned a $162.00 price target after noting that sell-off has gone too far versus Bluebird’s upside and growth opportunity. Since May 29th, the stock has fallen considerably from its height of $197. Can it regain its momentum? Albeit another underperfroming alternative to Blue might be Glaxo Smith Kline with a market cap of $100.91bn vs Blue's cap of $3.01bn. GSK rewards its shareholders with a healthy annual dividend yield of 5.48%.
Apple's stock price dropped slightly yesterday pre earnings but added about $2 in overnight trading. Fears of oversupply of iphones and supply company concerns seemed to be causing jitters in the stock.
Yep, that's insurance for you, they know how to stay ahead of the risks and still come out ahead, somewhat similar to casino owners. The house always wins...good for the investor not so great if you're making the insured consumer!
Not a fan of trying to time the market because you never know whats round the corner? Hurricane season, maybe? Having said that, I also am a fan of the insurance sector. It seems like one of the safer sectors out there today, and I agree best to go with the biggest and best performers long term. Just looking at that ETF, KBWP. Its up 8% year to date, and a solid 18% over 3 years, not bad performance by any means but with the top holdings being Chubb, Progressive, Ace and The Travellers I am liking it more and more. Sure you could find better performing etfs out there but with a lot more volatility? Energy? Healthcare? No thanks!
Latest Comments
We're Flirting With Another Recession
Agreed, the diminishing job creation numbers in the US would seem to be an indication of a worsening economy. But the real indicator and official definition of a recession is when there are two consecutive quarters of negative economic growth as measured by a country's GDP. Ironically, this can happen despite a buoyant stock market and in fact the S&P was up a whopping 9% in October. Perhaps, this is the final gasp for air in the stock-market before everything comes crashing down?
2 Stocks To Pick Up In The Wake Of Fallout From Valeant
You might be right about a knock on effect from the Valeant fallout story, although these companies are focusing on different areas of the market and not considered direct competitors. I expect we will continue to see volatility in the biopharm/healthcare sector going forwards. Amgen is only up 0.7% YTD. To avoid the pitfalls of volatile stocks, try to buy on the dip rather than the upswing, and hold for the longer term. Maybe after being hit so hard maybe Valeant is now a buy?
Amgen Wins FDA Approval For Skin Cancer Drug
Out of 15 analyst opinions, 2 are a strong buy, 7 are a buy, and 8 are a hold currently. I expect we will continue to see volatility in the biopharm/healthcare sector going forwards. Amgen is only up 0.7% YTD. To avoid the pitfalls of volatile stocks, try to buy on the dip rather than the upswing, and hold for the longer term. Over the past 5 yrs the stock is up 185%.
Bluebid Bio Shares Fall 4.3% After Gene Therapy Update
You're welcome.:>
General Communications - Chart Of The Day
The stock is up around 48% ytd but there's precious little analyst opinions on the stock with only one opinion - a hold. With a market cap of under $1 bn, is this a gem of a stock that's too small to matter? Look out for earnings release next week Nov 4th.
Stop Blaming OPEC For Low Prices
Nothing injects momentum into oil prices like regional conflict. Perhaps, we just don't have enough of these any more! (that's not a bad thing) True, Opec has a hand in influencing supply and demand but they are only part of the bigger story. Global demand is slowing, US fracking is supplying too much oil, and oil is being stockpiled. China's demand is also slowing as industrial output slows. One thing's for sure, the owners of the some 253 million cars and trucks in the US aren't complaining about sinking oil prices.
Bluebid Bio Shares Fall 4.3% After Gene Therapy Update
Blue bounced back yesterday up almost 3% perhaps as a result of Tuesday's research call: Bluebird Bio, Inc. was given a ‘double your money’ research call on Tuesday. But on the downside, Oppenheimer has the stock as an Outperform rating, and assigned a $162.00 price target after noting that sell-off has gone too far versus Bluebird’s upside and growth opportunity. Since May 29th, the stock has fallen considerably from its height of $197. Can it regain its momentum? Albeit another underperfroming alternative to Blue might be Glaxo Smith Kline with a market cap of $100.91bn vs Blue's cap of $3.01bn. GSK rewards its shareholders with a healthy annual dividend yield of 5.48%.
Apple's Report Adds To Tech's Earnings Momentum
Apple's stock price dropped slightly yesterday pre earnings but added about $2 in overnight trading. Fears of oversupply of iphones and supply company concerns seemed to be causing jitters in the stock.
The Insurance Industry Is A Sweet Spot For Investors Now
Yep, that's insurance for you, they know how to stay ahead of the risks and still come out ahead, somewhat similar to casino owners. The house always wins...good for the investor not so great if you're making the insured consumer!
The Insurance Industry Is A Sweet Spot For Investors Now
Not a fan of trying to time the market because you never know whats round the corner? Hurricane season, maybe? Having said that, I also am a fan of the insurance sector. It seems like one of the safer sectors out there today, and I agree best to go with the biggest and best performers long term. Just looking at that ETF, KBWP. Its up 8% year to date, and a solid 18% over 3 years, not bad performance by any means but with the top holdings being Chubb, Progressive, Ace and The Travellers I am liking it more and more. Sure you could find better performing etfs out there but with a lot more volatility? Energy? Healthcare? No thanks!